WA-KYMETA
26.10.2021 15:02:16 CEST | Business Wire | Press release
Kymeta (www.kymetacorp.com ), the communications company making mobile global, announced today the successful testing of private Long Term Evolution (LTE) small cell on Citizens Broadband Radio Service (CBRS), demonstrating a complete connectivity solution that provides users with more reliable and robust connectivity directly to their smartphone and CBRS capable devices.
The trial was performed at Kymeta headquarters with a Kymeta™ u8 terminal, an off-the-shelf core running on an ARM single board compute (SBC), and an Accelleran small cell. The system delivers a turnkey solution to enhance the user experience by combining a private LTE network with the Kymeta terminal for broadband backhaul. CBRS enables a private intranet for communications to users like first responder teams and features video, push-to-talk, voice, and messaging apps within the CBRS coverage area while reserving the backhaul capacity for internet communications. In addition to backhaul, the system includes a core at the edge, allowing users’ devices to be bridged together locally without routing traffic back to the network core.
“Kymeta is testing and driving future technology breakthroughs as we look forward into our roadmap,” said Lilac Muller, Ph.D., Vice President of Product Management at Kymeta. “Public safety, defense, and enterprise authenticated users will have more resiliency from a small cell that is as easy as scanning a QR code. Smartphones will interact with the hybrid satellite terminal and CBRS as a private LTE hub and have both satellite and cellular backhaul in one solution."
CBRS is a publicly available spectrum in the 3550-3700 MHz band (3.5 GHz band) designated by the Federal Communications Commission (FCC) in 2015 as a frequency for shared wireless, private broadband. It is divided among users into three tiers of authorization, including Incumbent Access users, Priority Access Licenses (PAL), and General Authorized Access (GAA).
The project's success in demonstrating private LTE small cell on CBRS to a standard smartphone, from a system integrated with the Kymeta u8 terminal, is a notable achievement in helping chart a path for future user connectivity strategies and further validates Kymeta's ability to develop future-proof solutions that satisfy the overwhelming demand for resilient mobile connectivity and improved user access.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company's satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company's flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com .
About Accelleran
Founded in 2013 and headquartered in Antwerp, Belgium, Accelleran provides disruptive software, solutions and services for Open 4G and 5G RAN and vRAN. The company’s unique approach supports genuine cloud-native deployment of RAN software components on the edge, in the cloud or embedded in the RRU. Accelleran’s commitment to openness enables multi-vendor radio deployments and delivers open RAN data for AI-enabled network algorithms. With a strong track record as the cellular industry’s leading RAN design, test and integration team, Accelleran is the natural choice for carrier-grade, reliable, portable and performant Radio Access Network Solutions and Services across multiple markets such as Private Networks, Fixed Wireless, Public Mobile, Neutral Host and IoT. For further information about Accelleran, please visit our website www.accelleran.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005335/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom